Replies to post #1948 on Cytodyn Inc (CYDY)

[tpizzazz24]

8B on approval of both P3 trials. I think that's more than fair.

[Inoviorulez]

I know I'm beating a dead horse here, but you are right. If the data is good Gilead stands to lose its 44% yearly revenue in the HIV space. After the blow it took from lower Hep C sales, and a falling share price along with $28 billion in the bank, I don't see why they wouldn't attempt to buy CYDY out.

[TheBioTechG]

Bucky- I'm of the same mind set as you. The CEO said on the latest conference call that the recent trial results have impressed himself as well as the KOL. Pending FDA drug approval of PRO 140, this will eat in to Gileads market share of HIV medications which constitutes nearly half of their yearly revenue (IMO). I've been trying to play devils advocate as much as possible, but the data is there with PRO 140. I anticipate that the next few weeks will be very exciting.